Semaglutide Did Not Slow Early Alzheimer’s Disease

CATEGORY: BRAIN & MENTAL HEALTH

Semaglutide—the drug in Ozempic, Wegovy and the Rybelsus tablet—did not slow early Alzheimer’s disease in two trials reported together in The Lancet. After two years of daily treatment, people taking the drug and people taking a placebo had declined by almost exactly the same amount: about two points on an 18-point dementia staging scale in both groups, with the difference between drug and placebo no larger than a tenth of a point in either trial.¹

The Hope That Grew Out of a Million Health Records

The trials, named evoke and evoke+, were built to test a hope with real numbers behind it. In an analysis of the health records of nearly 1.1 million Americans with type 2 diabetes, people prescribed semaglutide—a GLP-1 drug, one that mimics a gut hormone which signals fullness and helps steady blood sugar—went on to receive a first-time Alzheimer’s diagnosis 67% less often over three years than similar patients taking insulin, and 41% less often than patients taking other GLP-1 drugs.² The investigators set out to answer the question directly: does the drug actually shield the brain, or were the records reflecting something else about the people taking it?

A Coin Flip Carried Out in Forty Countries

Together the two near-identical trials enrolled 3,808 adults aged 55 to 85 at 566 clinics in 40 countries. All had mild memory and thinking problems or mild dementia, and all tested positive for amyloid, one of Alzheimer’s signature proteins, so the diagnosis was confirmed rather than assumed. Each person was assigned by chance—this was a randomized trial, not a study of choices people had made on their own—to a daily semaglutide tablet built up to 14 milligrams, or an identical placebo, with neither participants nor study staff knowing who had which. The main measure, taken at two years, came from the Clinical Dementia Rating’s Sum of Boxes: trained raters interview both the participant and someone who knows them well, then score memory, orientation, judgment, community life, home life and personal care on a scale running from 0 to 18, where higher means deeper into dementia.¹

Two Lines That Never Came Apart

In evoke, the semaglutide group and the placebo group each worsened by 2.3 points, and the 0.08-point difference in the drug’s favor was well within chance. In evoke+, the drug group worsened by 2.2 points and the placebo group by 2.1—a 0.10-point difference nominally favoring placebo, equally consistent with chance. The drug itself was plainly active: 36.5% of people on semaglutide recorded decreased weight versus 7.4% on placebo, with nausea in 24.3% versus 6.8% and reduced appetite in 33.1% versus 5.9%. Overall, 91.2% of participants on the drug reported at least one adverse event, versus 84.8% on placebo, and most events were the familiar digestive ones. What semaglutide did not do, in either trial, was bend the course of the disease, and a planned third-year extension was stopped once the two-year results were in.¹

Why a Million Records and One Coin Flip Disagree

Judging a drug from health records is like judging a health club by comparing members with everyone else in town: the members are fitter, but much of that fitness walked in the door with them. People prescribed semaglutide differed from people who were not—in weight, in medical attention, in overall health—and no statistical adjustment can be certain of removing every such difference. A coin flip removes them all at once, because chance does not care who is healthier. When the fair comparison was finally run, an association that had looked like 67% protection produced no measurable protection in people whose disease had already begun. Observational studies show association, not causation—and this is what that caveat looks like when it matters.¹

The Question the Trials Answered, and the One They Did Not

The verdict is specific: in adults aged 55 to 85 who already have symptoms of Alzheimer’s disease, daily oral semaglutide does not slow the decline. The trials found no sign that the drug harms the brain, and nothing in the result touches its established effects on blood sugar and weight. What they could not answer is whether GLP-1 drugs change the odds of developing dementia in the first place, because everyone enrolled was already ill; prevention in symptom-free people is a question only a different trial could settle.¹

Key Takeaways

• In two randomized trials totaling 3,808 adults with early symptomatic Alzheimer’s disease, a daily semaglutide tablet did not slow decline over two years—both groups worsened by about two points on an 18-point scale, with differences no larger than a tenth of a point.
• The trials were launched because health-record studies had linked semaglutide to up to 67% fewer first-time Alzheimer’s diagnoses; the randomized comparison did not bear that association out in people already ill.
• The result leaves open whether GLP-1 drugs influence dementia risk in people without symptoms—a question these trials were not designed to answer.
• Side effects matched the drug’s known profile, mostly digestive: 91.2% of participants on semaglutide reported at least one adverse event versus 84.8% on placebo.

References

1. Cummings JL, Atri A, Sano M, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026;407(10544):2167–2179. link
2. Wang W, Wang Q, Qi X, et al. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimer’s & Dementia. 2024;20(12):8661–8672. link